Q-1802

SHANGHAI, Dec. 20, 2022 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on development of bispecific antibodies and other engineered Biopharmaceuticals for the treatment of cancer, inflammation, and other serious disorders, today announced that Phase Ⅰ Clinical Data of its Q-1802 program will be presented at ASCO Gastrointestinal Cancers Symposium (ASCO-GI) hold at the San Francisco and online on January 19–21, 2023. The abstract will be found in 2023 ASCO Gastrointestinal Cancers Symposium–Meeting Abstracts (#382) and a brief of the abstract information is shown as below: Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs in patients with relapsed or refractory solid tumors Authors: Yakun Wang1, Jifang Gong1, Yuping Sun2, Jian Zhang3, Yanqiao Zhang4 ,Shuqin ni2, Jie Hou5, Xiaohua Chen5, Yusheng Wang6, Qin Yu7, Xiangdong Qu8, Yejie Du8, Li Wei8, Tao Yu8, Lin Shen1 Q-1802 is a humanized bispecific antibody targets both the tumor -specific antigen CLDN18.2 and the immune checkpoint PD-L1 Q-1802 has excellent safety, tolerability Q-1802 has excellent anti-tumor activity in CLDN18.2 positive GI patients About Q-1802 Q-1802, a humanized bispecific antibody, is the first FDA-approved and the first enter clinical trial Claudin18.2/PD-L1 bispecific antibody，as well as the first to present clinical data at ASCO annual meeting. It recruits multiple immune mechanisms to kill tumor cells, offering a novel therapeutic opportunity for Claudin18.2 positive solid tumors. Q-1802 exhibits high affinity and selectivity, and patients with low or high expression of CLDN18.2 can benefit from it. The current clinical phase I data verify both superior anti-tumor activities and excellent safety profiles. The molecular design of Q-1802 is rational and effective, the production process is robust with high yield. About QureBio Ltd. QureBio Ltd. is a clinical-stage biopharmaceutical company focusing on innovative biopharmaceuticals for urgent and unmet clinical needs, such as the treatment of refractory cancers, inflammation and other serious disorders. Founded by experienced scientists from the relevant fields, QureBio Ltd. has built up a series of proprietary technologies for engineered bio-macromolecules, including innovative platforms for bi-specific and tri-specific antibodies. Founded in 2017 with seed capital from Viva Bio-Innovator, QureBio Ltd. has since received a series of funds from Jundu Investment, Watson Capital, Shenzhen Capital Group, New value Capital,Bocom Industrial Investment (Hangzhou) Equity Investment Partnership, Suzhou Oriza Holdings, Hangzhou CAPITAL GuoShun, Zhuhai Longmen Capital Management, Shanghai Pudong Kechuang Group, Shenzhen Lihe Hongxin Venture and Three Rivers Capital. QureBio Ltd. Has secured a Series-B funding of nearly 200 million CNY. QureBio Ltd. engages in collaboration with partners to develop novel therapeutics for unmet medical needsand has on-going cooperation with a series of industrial partners including BRL Medicine, Precision Scientific, and Hengrui Pharmaceuticals. Contact Us: Tel: +86 21-61622561 BD： Email: [email protected] Website: Address: Building 30, Lane 1000, Zhangheng Road, Pudong New Area, Shanghai Postal Code : 201203 SOURCE QureBio Ltd.

SHANGHAI, May 31, 2022 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on bi-specific antibodies and other engineered bio-therapeutics for the treatment of cancer, inflammation, and other serious disorders, today announced that its Q-1802 clinical program was selected for presentation at American Society of Clinical Oncology (ASCO) Annual Meetings on June 3–7, 2022, and the abstract of relevant results for this study has been published on ASCO website ( ). The presentation will showcase the preliminary results of a first-in-human Phase 1a/1b, multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity Q-1802, a Claudin18.2/PD-L1 bi-specific therapeutic in patients with relapsed or refractory solid tumors after standard therapies. Professor Lin Shen from Peking University Cancer Hospital and Institute leads this study. The key data from the mono-therapy of Q-1802 in both dose-escalation and dose-expansion studies demonstrate excellent safety, tolerability, and preliminary anti-tumor activities of Q-1802 at the dose up to 10 mpk. The abstract for the study is found in 2022-ASCO-Annual –Meeting Abstracts (#2568), and the poster session information is listed below. First Author, Dr. Jifang Gong from the Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute will present the relevant results on Sunday, June 5, 2022. Session Title: Developmental Therapeutics—Immunotherapy Session Type: Poster Session Date: Sunday, June 5, 2022 Time: 8:00 AM - 11:00 AM, Chicago Time (CDT) Location: Hall A Abstract ID (Temp. ID): 2568 (368426) Poster Board #: 223 Role Responsibilities: Presenter Primary Track: Developmental Therapeutics—Immunotherapy Session begins on Jun 5, 2022 at 8:00 AM Chicago Time (CDT) Room: Hall A-14355 Persons: Dr. Jifang Gong Presenting from 8:00 AM - 11:00 AM, Chicago Time (CDT) About Q-1802 Q-1802, a humanized bi-specific antibody, is the first FDA-approved Claudin18.2/PD-L1 bi-specific therapeutic to enter clinical trial. In animal model studies, Q-1802 demonstrates both superior anti-tumor activities and excellent safety pro It recruits multiple immune mechanisms to kill tumor cells, offering a novel therapeutic opportunity for Claudin18.2 positive solid tumors. Q-1802 also exhibits robust physicochemical properties and superb productivity with titers exceeding 4 grams per liter. About QureBio Ltd. QureBio Ltd. is a clinical-stage biopharmaceutical company focusing on innovative biopharmaceuticals for urgent and unmet clinical needs, such as the treatment of refractory cancers, inflammation and other serious disorders. Founded by experienced scientists from the relevant fields, QureBio Ltd. has built up a series of proprietary technologies for engineered bio-macromolecules, including innovative platforms for bi-specific and tri-specific antibodies. Founded in 2017 with seed capital from Viva Bio-Innovator, QureBio Ltd. has since received a series of funds from Jundu Investment, Watson Capital, Shenzhen Capital Group, New value Capital, Bocom Industrial Investment (Hangzhou) Equity Investment Partnership, Suzhou Oriza Holdings, Hangzhou CAPITAL GuoShun, Zhuhai Longmen Capital Management, Shanghai Pudong Kechuang Group, Shenzhen Lihe Hongxin Venture and Three Rivers Capital. QureBio Ltd. has secured a Series-B funding of nearly 200 million CNY. QureBio Ltd. engages in collaboration with partners to develop novel therapeutics for unmet medical needs and has on-going cooperation with a series of industrial partners including BRL Medicine, BioMap, Precision Scientific, and Hengrui Pharmaceuticals, an industry leader in China.